David R. Plowchalk

1.9k total citations
27 papers, 1.4k citations indexed

About

David R. Plowchalk is a scholar working on Spectroscopy, Health, Toxicology and Mutagenesis and Pharmacology. According to data from OpenAlex, David R. Plowchalk has authored 27 papers receiving a total of 1.4k indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Spectroscopy, 6 papers in Health, Toxicology and Mutagenesis and 6 papers in Pharmacology. Recurrent topics in David R. Plowchalk's work include Analytical Chemistry and Chromatography (7 papers), Effects and risks of endocrine disrupting chemicals (6 papers) and Carcinogens and Genotoxicity Assessment (5 papers). David R. Plowchalk is often cited by papers focused on Analytical Chemistry and Chromatography (7 papers), Effects and risks of endocrine disrupting chemicals (6 papers) and Carcinogens and Genotoxicity Assessment (5 papers). David R. Plowchalk collaborates with scholars based in United States, United Kingdom and Switzerland. David R. Plowchalk's co-authors include Donald R. Mattison, Melvin E. Andersen, R. Scott Obach, Maurice Dickins, J.D. deBethizy, Karen Rowland Yeo, Ruth Hyland, Jack Cook, Susan Hurst and Alex Phipps and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of the American College of Cardiology and American Journal of Obstetrics and Gynecology.

In The Last Decade

David R. Plowchalk

27 papers receiving 1.3k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
David R. Plowchalk United States	20	330	270	264	248	195	27	1.4k
Azza A. K. El‐Sheikh Egypt	22	261 0.8×	447 1.7×	412 1.6×	255 1.0×	56 0.3×	77	1.8k
Su‐Jun Lee South Korea	24	806 2.4×	608 2.3×	478 1.8×	193 0.8×	108 0.6×	74	1.9k
Patricia K. Eagon United States	29	207 0.6×	458 1.7×	280 1.1×	55 0.2×	82 0.4×	69	2.0k
Josie L. Falany United States	25	830 2.5×	988 3.7×	350 1.3×	50 0.2×	132 0.7×	47	2.1k
T.C. Orton United Kingdom	16	292 0.9×	633 2.3×	274 1.0×	50 0.2×	205 1.1×	40	1.4k
Hongbing Wang United States	20	655 2.0×	384 1.4×	362 1.4×	50 0.2×	84 0.4×	55	1.4k
P. Czygan Germany	21	336 1.0×	333 1.2×	759 2.9×	55 0.2×	58 0.3×	83	1.8k
Μartine Aggerbeck France	25	156 0.5×	679 2.5×	209 0.8×	35 0.1×	238 1.2×	59	1.6k
Marie V. St–Pierre Switzerland	24	185 0.6×	552 2.0×	987 3.7×	314 1.3×	43 0.2×	43	1.9k
André Cordier Switzerland	16	150 0.5×	443 1.6×	132 0.5×	52 0.2×	124 0.6×	31	1.6k

Countries citing papers authored by David R. Plowchalk

Since Specialization

Citations

This map shows the geographic impact of David R. Plowchalk's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David R. Plowchalk with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David R. Plowchalk more than expected).

Fields of papers citing papers by David R. Plowchalk

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David R. Plowchalk. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David R. Plowchalk. The network helps show where David R. Plowchalk may publish in the future.

Co-authorship network of co-authors of David R. Plowchalk

This figure shows the co-authorship network connecting the top 25 collaborators of David R. Plowchalk. A scholar is included among the top collaborators of David R. Plowchalk based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with David R. Plowchalk. David R. Plowchalk is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Plowchalk, David R., et al.. (2023). Population PK/PD modeling of low‐density lipoprotein cholesterol response in hypercholesterolemic participants following administration of bococizumab, a potent anti‐PCSK9 monoclonal antibody. CPT Pharmacometrics & Systems Pharmacology. 12(12). 2013–2026. 5 indexed citations

Bass, Almasa, et al.. (2018). Pharmacokinetics, pharmacodynamics, and safety of bococizumab, a monoclonal antibody against proprotein convertase subtilisin/kexin type 9, in healthy subjects when administered in co‐mixture with recombinant human hyaluronidase: A phase 1 randomized trial. Health Science Reports. 1(9). e61–e61. 5 indexed citations

Ballantyne, Christie M., Joel Neutel, William Duggan, et al.. (2014). =EFFICACY AND SAFETY OF BOCOCIZUMAB (RN316/PF-04950615), A MONOCLONAL ANTIBODY AGAINST PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 IN STATIN-TREATED HYPERCHOLESTEROLEMIC SUBJECTS: RESULTS FROM A RANDOMIZED, PLACEBO-CONTROLLED, DOSE-RANGING STUDY (NCT: 01592240). Journal of the American College of Cardiology. 63(12). A1374–A1374. 16 indexed citations

Plowchalk, David R., et al.. (2014). Population pharmacokinetic and pharmacodynamic modeling of bococizumab (RN316/PF-04950615) in hypercholesterolemic subjects. Atherosclerosis. 235(2). e262–e262. 6 indexed citations

Zella, Julia B., et al.. (2014). Novel, Selective Vitamin D Analog Suppresses Parathyroid Hormone in Uremic Animals and Postmenopausal Women. American Journal of Nephrology. 39(6). 476–483. 13 indexed citations

Callegari, Ernesto, Amit S. Kalgutkar, Louis Leung, et al.. (2013). Drug Metabolites as Cytochrome P450 Inhibitors: A Retrospective Analysis and Proposed Algorithm for Evaluation of the Pharmacokinetic Interaction Potential of Metabolites in Drug Discovery and Development. Drug Metabolism and Disposition. 41(12). 2047–2055. 25 indexed citations

Plowchalk, David R. & Karen Rowland Yeo. (2012). Prediction of drug clearance in a smoking population: modeling the impact of variable cigarette consumption on the induction of CYP1A2. European Journal of Clinical Pharmacology. 68(6). 951–960. 42 indexed citations

Jones, Hannah M., Iain Gardner, Wendy T. Collard, et al.. (2011). Simulation of Human Intravenous and Oral Pharmacokinetics of 21 Diverse Compounds Using Physiologically Based Pharmacokinetic Modelling. Clinical Pharmacokinetics. 50(5). 331–347. 79 indexed citations

Fahmi, Odette A., Susan Hurst, David R. Plowchalk, et al.. (2009). Comparison of Different Algorithms for Predicting Clinical Drug-Drug Interactions, Based on the Use of CYP3A4 in Vitro Data: Predictions of Compounds as Precipitants of Interaction. Drug Metabolism and Disposition. 37(8). 1658–1666. 167 indexed citations

10.

Plowchalk, David R.. (2002). Development of a Physiologically Based Pharmacokinetic Model for Estradiol in Rats and Humans: A Biologically Motivated Quantitative Framework for Evaluating Responses to Estradiol and Other Endocrine-Active Compounds. Toxicological Sciences. 69(1). 60–78. 38 indexed citations

11.

Bogdanffy, Matthew S., David R. Plowchalk, R. Sarangapani, T B Starr, & Melvin E. Andersen. (2001). MODE-OF-ACTION–BASED DOSIMETERS FOR INTERSPECIES EXTRAPOLATION OF VINYL ACETATE INHALATION RISK. Inhalation Toxicology. 13(5). 377–396. 20 indexed citations

12.

Plowchalk, David R., et al.. (1997). Physiologically Based Modeling of Vinyl Acetate Uptake, Metabolism, and Intracellular pH Changes in the Rat Nasal Cavity. Toxicology and Applied Pharmacology. 142(2). 386–400. 50 indexed citations

13.

Bogdanffy, Matthew S., et al.. (1994). Dosimetry of Vinyl Acetate in The Nasal Passages of Rats: Comparison of in Vitro and in Vivo Methods of Quantifying Metabolism. Inhalation Toxicology. 6(sup1). 409–412. 1 indexed citations

14.

Plowchalk, David R. & Donald R. Mattison. (1992). Reproductive toxicity of cyclophosphamide in the C57BL/6N mouse: 1. Effects on ovarian structure and function. Reproductive Toxicology. 6(5). 411–421. 63 indexed citations

15.

Plowchalk, David R., et al.. (1992). Reproductive toxicity of cyclophosphamide in the C57BL/6N mouse: 2. Effects on uterine structure and function. Reproductive Toxicology. 6(5). 423–429. 71 indexed citations

16.

Plowchalk, David R., Melvin E. Andersen, & J.D. deBethizy. (1992). A physiologically based pharmacokinetic model for nicotine disposition in the Sprague-Dawley rat. Toxicology and Applied Pharmacology. 116(2). 177–188. 65 indexed citations

17.

Miller, Michael M., et al.. (1992). The effect of benzo(a)pyrene on murine ovarian and corpora lutea volumes. American Journal of Obstetrics and Gynecology. 166(5). 1535–1541. 26 indexed citations

18.

Plowchalk, David R. & Donald R. Mattison. (1991). Phosphoramide mustard is responsible for the ovarian toxicity of cyclophosphamide. Toxicology and Applied Pharmacology. 107(3). 472–481. 80 indexed citations

19.

Smith, Bill J., David R. Plowchalk, I.G. Sipes, & Donald R. Mattison. (1991). Comparison of random and serial sections in assessment of ovarian toxicity. Reproductive Toxicology. 5(4). 379–383. 48 indexed citations

20.

Mattison, Donald R., et al.. (1990). Reproductive Toxicity: Male and Female Reproductive Systems as Targets for Chemical Injury. Medical Clinics of North America. 74(2). 391–411. 60 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact